# Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT

> **NCT05896007** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 29 (estimated)

## Conditions studied

- PCNSL

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Rituximab
- **DRUG:** Methotrexate
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT05896007
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-13
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896007, "Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05896007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*